摘要
目的:研究心力衰竭合并心律失常患者采取胺碘酮与厄贝沙坦治疗的临床价值。方法:选择笔者所在医院2014年5月-2017年5月纳入的117例心力衰竭合并心律失常患者,按照随机数字法分为两组,研究组(n=58)患者采取胺碘酮与厄贝沙坦治疗,对照组(n=59)患者采取胺碘酮冶疗,对比两组临床治疗效果。结果:研究组总有效率为93.10%,高于对照组的81.36%,差异有统计学意义(χ~2=6.187,P<0.05);治疗后1、3、6个月研究组窦性心律维持率均高于对照组,差异均有统计学意义(χ~2=5.906、12.779、4.423,P<0.05)。结论:心力衰竭合并心律失常患者采取胺碘酮与厄贝沙坦治疗效果明显,快速缓解患者相关症状,改善窦性心律维持率,促进病情稳定,为预后提供保障。
Objective:To study the clinical value of Amiodarone combined with Irbesartan in cardiac failure with arrhythmia.Method:A total of 117 cardiac failure patients with arrhythmia treated from May 2014 to May 2017 in the author’s hospital were selected and randomly assigned to two groups.The study group(n=58)took Amiodarone plus Irbesartan,the control group(n=59)took Amiodarone.The therapeutic effect was probed.Result:The total effective rate in the study group was 93.10%,significantly higher than 81.36%of the control group,the difference was statistically significant(X2=6.187,P<0.05).After 1,3 and 6 months of treatment,the maintenance rate of sinus rhythm in the study group were significantly higher than those of the control group,the differences were statistically significant(X2=5.906,12.779,4.423,P<0.05).Conclusion:The Amiodarone combined with Irbesartan can quickly relieve the related symptoms,improve the maintenance rate of sinus rhythm,stabilize the illness state and keep the patients’prognosis.
作者
杨运堂
YANG Yuntang(The Central Hospital of Beijing Municipal Administration of Prisons,Beijing 100054,China)
出处
《中外医学研究》
2018年第19期48-49,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
